Heart Failure

Heart Failure

The prevalence of heart failure (HF) continues to increase over time1 and affects >60 million people each year2.

Therefore, being aware of the latest data in the HF space and different treatment options is important in order to be able to apply findings to clinical practice when making treatment decisions for patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease, especially HF.

This section is supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company Alliance

Boehringer Ingelheim

Content on this section was partly provided by Boehringer Ingelheim. For any follow up questions please contact your local Boehringer Ingelheim representative.

Review articles


Systematic Analysis


Clinical Case Study

Press Announcements

Study Design

1.Heart disease and stroke statistics-2020 update: a report from the American Heart Association

Virani SS, Alonso A, Benjamin EJ, et al. Circulation 2020;141:e139-e596.


2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211-59.


Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

Creative Commons Licence

Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1–5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6–8 The prevalence of T2D among patients with HF is as high as 40–45% and that of HF in patients with T2D is reported to be 10–23%.8 Patients wit

The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF

Creative Commons Licence

Heart failure (HF) and AF are two conditions that are increasing in prevalence worldwide.1,2 They frequently co-exist and in recent years, the clinical and physiological intersection between arrhythmia and HF has become an area of renewed interest, particularly as interventional treatments for rhythm disorders have advanced and moved into the mainstream of cardiac management.

Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip

Creative Commons Licence

In patients with heart failure and reduced left ventricular ejection fraction (LVEF), secondary (functional) mitral regurgitation, in which the mitral valve leaflets and chordae are essentially normal, is the result of functional and structural alterations of the left ventricle (LV).

Exercise Training and Heart Failure: A Review of the Literature

Creative Commons Licence

Congestive heart failure (CHF) is a progressive cardiovascular disease with significant morbidity and mortality that affects an increasing amount of people worldwide. There are approximately 6.5 million people in the US, more than 14 million people in Europe, and 26 million people worldwide who are living with heart failure, and the prevalence continues to grow.1–3 In the US alone, there were 960,000 new cases of CHF diagnosed in 2017, and this is expected to continue to increase year on year in the ageing population.

Biomarkers in Routine Heart Failure Clinical Care

Creative Commons Licence

The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either diagnose an illness or to monitor progress. Tijsen et al.

Heart Failure and Problems with Frailty Syndrome: Why it is Time to Care About Frailty Syndrome in Heart Failure

Creative Commons Licence

The first paper that referred to the problem of ‘frail elderly patients’ was published in 1953, and frailty syndrome (FS) was first described in the 1990s.1,2 Although it has long been recognised and diagnosed, no consensus definition of this clinical syndrome has been established.

Subclinical Left Ventricular Dysfunction During Chemotherapy

Creative Commons Licence

Advances in the early detection and treatment of cancer have improved overall survival in cancer patients. Nevertheless, cardiovascular diseases appear as the major cause of morbidity and mortality among cancer survivors.1 Left ventricular (LV) dysfunction and/or heart failure are the most common cardiovascular complications after administration of chemotherapies. The term ‘cardiotoxicity’ is generally used to refer to LV dysfunction.

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Creative Commons Licence

With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the management of T2D has been undergoing an important transformation from simply targetin


Subscribe to RSS - Heart Failure